Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction

NCT05356520 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2024-11-08

No results posted yet for this study

Summary

The incidence of esophagogastric junction has been increasing in recent years, and surgery is an important method for the treatment of adenoma at the esophagogastric junction. Currently, there is a great controversy about the surgical method of Siewert II, mainly choosing the right chest or the left chest for thoracic surgery. Therefore, it is of great significance to further study the surgical methods of Siewert II esophagogastric junction adenoma. Objective: To compare the safety, feasibility, and clinical efficacy of endoscopic Ivor-Lewis versus laparoscopic extended abdominal gastrectomy for Siewert type Ⅱadenocarcinoma at the resectable esophagogastric junction.

Conditions

  • Siewert Type II Adenocarcinoma of Esophagogastric Junction

Interventions

PROCEDURE

Endoscopy Ivor-lewis

Endoscopy Ivor-lewis

PROCEDURE

Laparoscopic transabdominal enlarged gastrectomy

Laparoscopic transabdominal enlarged gastrectomy

Sponsors & Collaborators

  • Tang-Du Hospital

    collaborator OTHER
  • Henan Provincial People's Hospital

    collaborator OTHER
  • General Hospital of Ningxia Medical University

    collaborator OTHER
  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER
  • The First Affiliated Hospital of Shanxi Medical University

    collaborator OTHER
  • Xijing Hospital of Digestive Diseases

    lead OTHER

Principal Investigators

  • xiaohua li, MD,PH.D · Xijing Hospital

  • xianli he, MD,PH.D · Tang-Du Hospital

  • peichun sun, MD,PH.D · Henan Provincial People's Hospital

  • lei wang, MD,PH.D · General Hospital of Ningxia Medical University

  • xuejun sun, MD,PH.D · First Affiliated Hospital of Xi 'an Jiaotong University

  • he huang, MD,PH.D · The First Affiliated Hospital of Shanxi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2025-05-31
Completion
2028-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05356520 on ClinicalTrials.gov